Basic Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. Jul 24, 2025; 16(7): 107109
Published online Jul 24, 2025. doi: 10.5306/wjco.v16.i7.107109
Figure 1
Figure 1 Thymopoietin protein in The Human Protein Atlas showed high expression in papillary thyroid carcinoma. A and B: Normal thyroid tissue; C and D: Papillary thyroid carcinoma tissue.
Figure 2
Figure 2 Thymopoietin protein in immunohistochemistry is highly expressed in papillary thyroid carcinoma. A and B: Thyroid cancer tissue; C and D: Normal thyroid tissue; E: Represents horizontal violin diagram; F: Thymopoietin differential receiver operating characteristic curve between papillary thyroid carcinoma (PTC) and non-PTC.
Figure 3
Figure 3 Thymopoietin mRNA exhibits higher expression in papillary thyroid carcinoma. A: Comparison with normal tissues shows higher thymopoietin (TMPO) mRNA expression in papillary thyroid carcinoma (PTC); B and C: Bias tests reveal no significant publication bias; D: Summary receiver operating characteristic indicates TMPO has discriminative capability in PTC. SMD: Standardized mean difference; SROC: Summary receiver operating characteristic.
Figure 4
Figure 4 Diagnostic test evaluation of thymopoietin. A: Sensitivity and specificity; B: Positive likelihood ratio and negative likelihood ratio.
Figure 5
Figure 5  Gene Set Enrichment Analysis results for thymopoietin.
Figure 6
Figure 6  Analysis of thymopoietin protein interaction network.
Figure 7
Figure 7 Growth of thymopoietin in papillary thyroid carcinoma cell lines and cell line growth inhibition after knockout of the thymopoietin gene based on Crispr knockout screen technology. A: Based on Cancer Cell Line Encyclopedia results; B: Based on Crispr knockout screen results.